Effects of hormone replacement therapy on left ventricular diastolic function in postmenopausal women: a systematic review and meta-analysis

References

• Obokata M, Reddy YNV, Borlaug BA. Diastolic dysfunction and heart failure with preserved ejection fraction: understanding mechanisms by using noninvasive methods. JACC Cardiovasc Imaging. 2020;13:245–257.
   PubMed Web of Science ®Google Scholar
• Gevaert AB, Boen JRA, Segers VF, et al. Heart failure with preserved ejection fraction: a review of cardiac and noncardiac pathophysiology. Front Physiol. 2019;10:638
   PubMed Web of Science ®Google Scholar
• Tanase DM, Radu S, Al Shurbaji S, et al. Natriuretic peptides in heart failure with preserved left ventricular ejection fraction: from molecular evidences to clinical implications. IJMS. 2019;20(11):2629.
   Google Scholar
• De Bellis A, De Angelis G, Fabris E, et al. Gender-related differences in heart failure: beyond the "one-size-fits-all" paradigm. Heart Fail Rev. 2020;25(2):211–245.
   Web of Science ®Google Scholar
• Tadic M, Cuspidi C, Plein S, et al. Sex and heart failure with preserved ejection fraction: from pathophysiology to clinical studies. JCM. 2019;8(6):792.
   Google Scholar
• Merz AA, Cheng S. Sex differences in cardiovascular ageing. Heart. 2016;102(11):825–831.
   PubMed Web of Science ®Google Scholar
• Beale AL, Meyer P, Marwick TH, et al. Sex differences in cardiovascular pathophysiology: why women are overrepresented in heart failure with preserved ejection fraction. Circulation. 2018;138(2):198–205.
   PubMed Web of Science ®Google Scholar
• Maslov PZ, Kim JK, Argulian E, et al. Is cardiac diastolic dysfunction a part of post-menopausal syndrome? JACC Heart Fail. 2019;7(3):192–203.
   PubMed Web of Science ®Google Scholar
• White WB, Hanes V, Chauhan V, et al. Effects of a new hormone therapy, drospirenone and 17 beta-estradiol, in postmenopausal women with hypertension. Hypertension. 2006;48(2):246–253.
   PubMed Web of Science ®Google Scholar
• Kenchaiah S, Vasan RS. Heart Failure in women-insights from the Framingham Heart Study. Cardiovasc Drugs Ther. 2015;29(4):377–390.
   PubMed Web of Science ®Google Scholar
• Hirokawa M, Daimon M, Lee SL, et al. Early menopause does not influence left ventricular diastolic dysfunction: A clinical observational study in healthy subjects. J Cardiol. 2016;68(6):548–553.
   PubMed Web of Science ®Google Scholar
• Shamseer L, Moher D, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (Prisma-P) 2015:elaboration and explanation. BMJ. 2015;349:g7647–g7647.
   PubMed Web of Science ®Google Scholar
• Alecrin IN, Aldrighi JM, Caldas MA, et al. Acute and chronic effects of oestradiol on left ventricular diastolic function in hypertensive postmenopausal women with left ventricular diastolic dysfunction. Heart. 2004;90(7):777–781.
   PubMed Web of Science ®Google Scholar
• Duygu H, Akman L, Ozerkan F, et al. Comparison of the effects of new and conventional hormone replacement therapies on left ventricular diastolic function in healthy postmenopausal women: a Doppler and ultrasonic backscatter study. Int J Cardiovasc Imaging. 2009; 25(4):387–396.
   PubMed Web of Science ®Google Scholar
• Muia N, Jr, Modena MG, Aveta P, et al. Effects of transdermal 17beta-estradiol on left ventricular anatomy and performance in hypertensive women. Hypertension. 1999;34(5):1041–1046.
   PubMed Web of Science ®Google Scholar
• Modena MG, Molinari R, Muia N, et al. Double-blind randomized placebo-controlled study of transdermal estrogen replacement therapy on hypertensive postmenopausal women. Am J Hypertension. 1999;12(10):1000–1008.
   PubMed Web of Science ®Google Scholar
• Fisman EZ, Tenenbaum A, Shapira I, et al. Lack of effects of transdermal estradiol on diastolic function: a randomized placebo-controlled double-blind short-term trial. Climacteric. 1999;2(3):174–180.
   PubMedGoogle Scholar
• Taskin O, Muderrisoglu H, Akar M, et al. Comparison of the effects of tibolone and estrogen replacement therapy on echocardiographic basic cardiac functions in post-menopausal women: a randomized placebo controlled study. Maturitas. 2004;48(4):354–359.
   PubMed Web of Science ®Google Scholar
• Aldrighi JM, Alecrin IN, Caldas MA, et al. Effects of estradiol on myocardial global performance index in hypertensive postmenopausal women. Gynecol Endocrinol. 2004;19(5):282–292.
   PubMed Web of Science ®Google Scholar
• Vogelvang, Marius J van der Mooren, Otto Kamp, et al. Effects of oral and transdermal low-dose estrogen therapy on echocardiographic parameters of cardiac function. Fertil Steril. 2003;80(3):546–553.
   Google Scholar
• Nicola Muia, Modena, Aveta, et al. Effects of transdermal 17beta-estradiol on left ventricular anatomy and performance in hypertensive women. Hypertension. 1999 ;34(5):1041–1046.
   Google Scholar
• Nudy M, Chinchilli VM, Foy AJ. A systematic review and meta-regression analysis to examine the 'timing hypothesis' of hormone replacement therapy on mortality, coronary heart disease, and stroke. Int J Cardiol Heart Vasc. 2019;22:123–131.
   PubMed Web of Science ®Google Scholar
• Keck C, Taylor M. Emerging research on the implications of hormone replacement therapy on coronary heart disease. Curr Atheroscler Rep. 2018;20(12):57
   PubMed Web of Science ®Google Scholar
• Lesiak M, Mariola RL, Podkowa N. [Hormone replacement therapy and cardio-vascular disease]. Ginekol Pol. 2016;87(1):59–64.
   PubMed Web of Science ®Google Scholar
• Gregori M, Tocci G, Marra A, et al. Inadequate RAAS suppression is associated with excessive left ventricular mass and systo-diastolic dysfunction. Clin Res Cardiol. 2013;102(10):725–733.
   PubMed Web of Science ®Google Scholar
• Upadhya B, Rocco MV, Pajewski NM, for the SPRINT Research Group, et al. Effect of intensive blood pressure reduction on left ventricular mass, structure, function, and fibrosis in the sprint-heart. Hypertension. 2019;74(2):259–276.
   Web of Science ®Google Scholar
• Shin E, Ko KS, Rhee BD, et al. Different effects of prolonged β-adrenergic stimulation on heart and cerebral artery. Integr Med Res. 2014;3(4):204–210.
   PubMedGoogle Scholar
• González-Fernández RA, Rivera M, Rodríguez PJ, et al. Prevalence of ectopic ventricular activity after left ventricular mass regression. Am J Hypertens. 1993;6(4):308–313.
   PubMed Web of Science ®Google Scholar
• Savji N, Meijers WC, Bartz TM, et al. The association of obesity and cardiometabolic traits with incident HFpEF and HFrEF. J Am Coll Cardiol HF. 2018;6(8):701–709.
   Google Scholar
• Ho JE, Gona P, Pencina MJ, et al. Discriminating clinical features of heart failure with preserved vs. reduced ejection fraction in the community. Eur Heart J. 2012;33(14):1734–1741.
   PubMed Web of Science ®Google Scholar
• Hall PS, Nah G, Howard BV, et al. Reproductive factors and incidence Heart Failure Hospitalization in the Women's Health Initiative. J Am Coll Cardiol. 2017;69(20):2517–2526.
   PubMed Web of Science ®Google Scholar
• Zhao Z, Wang H, Jessup JA, et al. Role of estrogen in diastolic dysfunction. Am J Physiol Heart Circ Physiol. 2014;306(5):H628–40.
   PubMed Web of Science ®Google Scholar
• Abbate A, Narula J. Role of apoptosis in adverse ventricular remodeling. Heart Fail Clin. 2012;8(1):79–86.
   PubMed Web of Science ®Google Scholar
• Li S, Gupte AA. The role of estrogen in cardiac metabolism and diastolic function. Methodist Debakey Cardiovasc J. 2017;13(1):4–8.
   PubMedGoogle Scholar
• Simon JN, Duglan D, Casadei B, et al. Nitric oxide synthase regulation of cardiac excitation-contraction coupling in health and disease. J Mol Cell Cardiol. 2014;73:80–91.
   PubMed Web of Science ®Google Scholar
• Li J, Jubair S, Janicki JS. Estrogen inhibits mast cell chymase release to prevent pressure overload-induced adverse cardiac remodeling. Hypertension. 2015;65(2):328–334.
   PubMed Web of Science ®Google Scholar
• Wang S, Wang Y, Jiang J, et al. 15-HETE protects rat pulmonary arterial smooth muscle cells from apoptosis via the PI3K/Akt pathway. Prostaglandins Other Lipid Mediat. 2010;91(1-2):51–60.
   PubMed Web of Science ®Google Scholar
• van Rooij E, Fielitz J, Sutherland LB, et al. Myocyte enhancer factor 2 and class II histone deacetylases control a gender-specific pathway of cardioprotection mediated by the estrogen receptor. Circ Res. 2010;106(1):155–165.
   PubMed Web of Science ®Google Scholar
• Wang H, Jessup JA, Lin MS, et al. Activation of GPR30 attenuates diastolic dysfunction and left ventricle remodelling in oophorectomized mRen2.Lewis rats. Cardiovasc Res. 2012;94(1):96–104.
   PubMed Web of Science ®Google Scholar